inactiv
vaccin
sever
acut
respiratori
syndrom
sar
associ
coronaviru
sarscov
evalu
rhesu
monkey
monkey
inocul
intramuscularli
im
g
vaccin
pb
control
boost
day
week
challeng
strain
sarscov
humor
mucos
immun
respons
clinic
sign
chemic
indic
viremia
monitor
follow
immun
challeng
control
anim
receiv
pb
develop
atyp
sarcov
infect
viral
challeng
accord
clinic
virolog
patholog
find
systemat
side
effect
observ
vaccin
anim
postimmun
even
high
dose
g
g
dosag
vaccin
elicit
sarscov
specif
immun
respons
viral
infect
compar
partial
immun
elicit
g
dose
result
show
inactiv
vaccin
induc
effect
concomit
humor
mucos
immun
sarscov
infect
safe
monkey
vaccin
mayb
good
candid
clinic
trial
first
emerg
lifethreaten
highli
contagi
epidem
centuri
sever
acut
respiratori
syndrom
sar
spread
countri
across
five
contin
excess
morbid
mortal
effort
intern
consortium
laboratori
new
type
coronaviru
sarsassoci
coronaviru
sarscov
identifi
caus
agent
convent
coronavirus
caus
econom
devast
diseas
livestock
poultri
laboratori
rodent
sever
coronavirus
caus
fatal
system
diseas
anim
includ
felin
infecti
periton
viru
fipv
hemagglutin
encephalomyel
viru
hev
swine
strain
avian
infecti
bronchiti
viru
ibv
mous
hepat
viru
mhv
gener
coronaviru
caus
diseas
one
anim
speci
immunocompet
host
infect
elicit
neutral
antibodi
cellmedi
immun
respons
kill
infect
cell
immunocompet
sar
patient
neutral
antibodi
detect
week
onset
diseas
patient
recov
without
hospit
base
learn
anim
coronaviru
serolog
respons
sar
patient
control
sar
seem
like
achiev
vaccin
lack
understand
pathogenesi
sar
etiolog
effort
toward
develop
sar
vaccin
express
viral
protein
vitro
introduc
attenu
mutat
viru
engin
viru
genom
vector
requir
consider
research
setup
time
therefor
classic
approach
use
inactiv
cellcultur
base
sar
viru
like
fastest
easiest
way
sar
vaccin
develop
ground
experi
mani
commerci
vaccin
includ
inactiv
oral
polio
vaccin
rabi
vaccin
present
studi
report
preclin
evalu
inactiv
vaccin
candid
sarscov
immunogen
safeti
protect
nonhuman
primat
rhesu
monkey
viru
use
candid
inactiv
sarscov
vaccin
sarscov
strain
isol
blood
first
sar
patient
zhejiang
provinc
china
vaccin
formaldehyd
inactiv
whole
viru
prepar
cultur
vero
cell
provid
wuhan
institut
biolog
product
hubei
provinc
viru
use
challeng
chines
sarscov
repres
strain
isol
urin
acutephas
sar
patient
epidem
china
ningxia
provinc
titer
prepar
pfuml
anim
obtain
yunnan
anim
cultiv
center
yunnan
china
eighteen
rhesu
monkey
number
half
male
half
femal
bodi
weight
rang
kg
use
studi
monkey
test
neg
antibodi
sarscov
anim
hous
individu
cage
biosafeti
level
three
contain
facil
maintain
constant
room
temperatur
dark
photoperiod
fed
appl
pellet
diet
everi
day
handl
bleed
immun
challeng
monkey
anesthet
intramuscularli
im
ketamin
hydrochlorid
mgkg
procedur
involv
probabl
infecti
sampl
conduct
laboratori
anim
immun
accord
protocol
tabl
eighteen
monkey
random
six
group
monkey
receiv
highest
dose
vaccin
use
evalu
safeti
vaccin
inject
region
depil
advanc
local
reaction
vaccin
evalu
day
postimmun
immun
monkey
two
control
monkey
challeng
strain
sar
cov
dose
plaqueform
unit
pfu
per
anim
intratrach
administr
viru
perform
cricothyroid
membran
punctur
anim
sacrif
necropsi
day
postchalleng
venou
blood
collect
day
postimmun
day
postchalleng
serum
separ
store
c
subsequ
test
addit
lightli
heparin
blood
sampl
iu
heparin
per
ml
blood
collect
hematolog
examin
immun
two
time
postchalleng
nasopharyng
secret
collect
asept
swab
day
postimmun
day
postchalleng
wash
ml
salin
centrifug
rpm
min
supernat
store
c
iga
elisa
reversetranscriptas
polymeras
chain
reaction
rtpcr
assay
mixtur
fece
urin
sampl
collect
pre
postimmun
day
postchalleng
necropsi
conduct
day
postchalleng
tissu
sampl
obtain
lung
kidney
liver
heart
brain
patholog
examin
fix
formalin
embed
section
stain
hematoxylin
eosin
tissu
sampl
lung
kidney
also
frozen
rtpcr
assay
viru
isol
vero
cell
cultur
humor
mucos
immun
respons
assay
convent
indirect
elisa
describ
purifi
sarscov
antigen
provid
institut
microbiolog
epidemiolog
chines
militari
medic
academi
beij
china
serum
sampl
test
igg
duplic
serial
dilut
pb
contain
bsa
nasopharyng
iga
test
directli
supernat
wash
obtain
swab
purifi
viral
antigen
dilut
gml
sodium
carbon
buffer
ph
prior
use
flatbottom
micropl
costar
corn
inc
usa
coat
l
antigen
solut
c
h
plate
block
lwell
fb
pb
h
c
wash
pb
contain
tween
pbst
plate
incub
c
h
l
serum
dilut
nasolpharyng
wash
plate
wash
incub
c
h
horseradish
peroxidaseconjug
goat
antimonkey
affin
purifi
igg
bethyl
laboratori
inc
usa
dilut
tpb
buffer
contain
bsa
horseradish
peroxidaseconjug
goat
antimonkey
affin
purifi
iga
kpl
europ
dilut
wash
pbst
well
develop
tmb
min
room
temperatur
dark
reaction
stop
addit
l
h
optic
densiti
od
color
product
measur
nm
use
plate
reader
rayto
corpor
igg
elisa
titer
express
reciproc
highest
dilut
od
valu
least
neg
control
signific
mucos
iga
antibodi
respons
defin
least
control
preinocul
sampl
monkey
use
control
neutral
antibodi
detect
inhibit
cpe
cultur
cell
monolay
inocul
challeng
viru
strain
serum
sampl
day
postimmun
heatinactiv
serial
dilut
mix
viru
water
incub
h
c
mixtur
inocul
onto
plate
cell
use
eight
well
per
dilut
cultur
held
c
co
daili
microscop
examin
cytopath
effect
cpe
viru
control
serum
show
complet
cpe
maximum
dilut
serum
complet
prevent
cpe
testwel
calcul
reed
muench
formula
viru
control
serum
show
complet
cpe
vitro
quantit
determin
monkey
serum
assay
quantit
sandwich
elisa
biosourc
intern
inc
usa
assay
perform
accord
manufactur
instruct
od
valu
nm
measur
elisa
plate
reader
describ
standard
curv
plot
light
od
valu
standard
sampl
use
calcul
concentr
cytokin
separ
follow
immun
challeng
anim
monitor
daili
clinic
sign
local
reaction
inject
site
chang
activ
rectal
temperatur
appetit
rash
frequenc
defec
stool
consist
etc
hematolog
examin
conduct
sysmex
liver
kidney
function
measur
blood
level
alanin
aminotransferas
alt
aspart
aminotranferas
ast
total
protein
tp
albumin
alb
gamma
glutamyl
transferas
ggt
urea
creatinin
clearanc
cr
rayto
corpor
shenzhen
averag
level
anim
group
immun
use
normal
level
chest
xray
exam
posterioranterior
posit
later
posit
perform
anim
sacrific
evid
viru
blood
nasopharyg
swab
mixtur
fece
urin
sampl
detect
reversetranscriptas
polymeras
chain
reaction
total
rna
kit
promega
trizol
kit
invitrogen
use
rna
extract
differ
sampl
random
primer
use
prepar
complementari
dna
templat
pcr
forward
revers
primer
use
rtpcr
nucleotid
nucleotid
respect
revers
transcript
conduct
c
h
c
min
amplif
cdna
perform
reaction
condit
c
min
follow
cycl
c
c
c
min
c
extend
min
one
hundr
microlit
per
well
serum
filter
nasopharyg
wash
tissu
homogen
inocul
onto
vero
cell
monolay
plate
costar
corn
inc
usa
incub
c
h
co
incub
inoculum
replac
complet
mem
gibco
contain
bovin
serum
cultur
plate
observ
day
blindli
passag
two
time
sarscov
specif
cytopathogen
effect
cpe
appear
tissu
histolog
immunohistochem
assay
perform
describ
previous
statist
comparison
wbc
count
pre
postimmun
post
challeng
group
iga
od
valu
cytokin
profil
differ
vaccin
dosag
perform
oneway
anova
spss
softwar
signific
set
p
monkey
surviv
intramuscular
innocul
candid
vaccin
dose
g
challeng
activ
sarscov
strain
pfu
time
necropsi
week
later
follow
immun
anim
appear
normal
activ
appetit
normal
weight
gain
systemat
complic
observ
specif
none
monkey
show
skin
rash
vaccin
inject
site
high
dose
g
caus
mild
local
reaction
indur
less
cm
diamet
hematolog
assay
show
signific
differ
preand
postimmun
group
fig
elev
serum
concentr
alt
ast
tp
alb
ggt
ruea
cr
greater
twice
mean
preimmun
level
data
shown
must
note
howev
characterist
vari
among
monkey
follow
live
viru
challeng
remark
chang
observ
rectal
temperatur
vaccineimmun
anim
clinic
symptom
cough
lethargi
rash
shown
vaccin
anim
likewis
normal
bodi
weight
gain
observ
vaccin
anim
howev
pbsinocul
control
anim
although
overt
clinic
respiratori
symptom
appear
minor
lethargi
loos
stool
observ
anim
day
postchalleng
monkey
temporari
skin
rash
signific
chang
bodi
temperatur
monkey
develop
fever
c
level
challeng
day
postchalleng
bodi
weight
monkey
decreas
slightli
fever
develop
obviou
chang
observ
monkey
live
viru
challeng
hematolog
assay
show
reduct
white
blood
cell
wbc
count
anim
receiv
g
vaccin
p
chang
measur
immun
group
control
monkey
transient
drop
wbc
count
detect
day
postchalleng
rapid
increas
increas
lymphocyt
classif
observ
day
fig
compar
averag
level
anim
preimmun
serum
biochem
indic
show
signific
increas
day
sacrific
data
shown
chest
xray
found
radiolog
patholog
abnorm
found
immun
anim
challeng
fig
focal
thicken
derang
streak
identifi
lung
two
pbscontrol
monkey
challeng
tissu
sampl
obtain
necropsi
affect
region
demonstr
xray
show
wall
pulmonari
alveoli
thicken
obvious
due
edema
alveolar
epithelia
prolifer
interstiti
cell
interstiti
lymphocyt
macrophag
inflammatori
infiltr
hyalinemembran
format
alveolar
wall
fig
immunohistochem
analysi
show
sarscov
antigen
alveolar
epithelia
fig
remark
lesion
shown
tissu
specif
amplif
product
obtain
rtpcr
sampl
pbscontrol
monkey
challeng
viru
tabl
furthermor
viru
isol
lung
tissu
anim
vero
cell
cultur
cpe
vero
cell
first
note
day
day
subcultur
tissu
specimen
anim
presenc
sarscov
rna
sampl
pcr
indic
absenc
nd
done
list
tabl
pbscontrol
monkey
remain
neg
sarscov
igg
antibodi
day
prechalleng
period
vaccin
monkey
develop
detect
igg
titer
day
post
first
immun
two
anim
receiv
g
vaccin
becam
igg
neg
second
immun
remain
neg
day
post
first
immun
result
suggest
differ
level
immun
respons
among
monkey
monkey
receiv
g
vaccin
demonstr
specif
igg
respons
day
post
first
immun
antibodi
titer
elev
gradual
second
immun
anim
receiv
g
vaccin
exhibit
high
level
antibodi
titer
day
post
first
immun
compar
three
four
anim
receiv
g
vaccin
two
four
anim
receiv
g
vaccin
increas
dose
appear
enhanc
immun
respons
antibodi
titer
day
indic
g
inactiv
vaccin
immunogen
g
vaccin
also
detect
igg
ab
level
day
follow
inocul
ab
level
increas
obvious
anim
gdose
group
anim
gdose
group
nasopharyng
antibodi
respons
intramuscular
vaccin
list
fig
five
immun
monkey
sarscov
specif
secretori
iga
siga
antibodi
fig
immun
inactiv
sarscov
vaccin
differ
level
neutral
antibodi
detect
day
three
immun
group
fig
found
antisera
show
variou
abil
inhibit
fig
sarscov
specif
siga
respons
nasopharyng
wash
initi
immun
cytopath
effect
mediat
sarscov
cell
higher
dosag
vaccin
induc
higher
level
neutral
antibodi
titer
fig
g
vaccin
appear
largest
neutraliz
activ
antibodi
level
day
g
vaccin
indic
half
level
day
day
neutral
titer
g
dose
group
significantli
lower
two
higher
dose
group
p
determin
helper
type
respons
cytokin
releas
serum
quantifi
sandwich
elisa
initi
immun
serum
monkey
receiv
g
g
vaccin
show
significantli
increas
product
significantli
higher
preimmun
level
p
respect
continu
increas
second
immun
serum
monkey
receiv
g
vaccin
demonstr
significantli
increas
ifn
fig
neutral
ab
rhesu
monkey
serum
immun
titer
express
reciproc
highest
dilut
cpe
complet
inhibit
testwel
data
present
mean
se
group
second
immun
p
obviou
chang
observ
anim
pb
control
group
hand
level
produc
preor
postvaccin
three
immun
group
control
group
exhibit
signific
chang
fig
although
signific
sar
outbreak
none
isol
case
result
death
secondari
transmiss
resurg
sar
lead
major
epidem
remain
possibl
develop
effect
vaccin
sarscov
crucial
prevent
futur
epidem
earli
studi
rodent
success
reproduc
sar
clinic
spectrum
andor
patholog
nonhuman
primat
show
great
valu
model
sar
infect
patholog
suitabl
monkey
model
sarscov
vaccin
test
also
describ
accord
summari
technic
meet
sar
anim
model
held
februari
sar
model
infect
mice
effect
monkey
avail
howev
develop
clinic
diseas
model
need
address
factor
might
affect
outcom
sarscov
infect
differ
model
differ
laboratori
time
necropsi
postchalleng
strain
viru
use
genet
background
specif
pathogen
free
spf
statu
age
anim
scv
challeng
dose
stress
anim
similar
studi
rhesu
monkey
studi
experiment
infect
chines
strain
sarscov
replic
sever
ill
seen
human
sar
patient
pbscontrol
monkey
develop
lowgrad
fever
mild
clinic
sign
show
evid
viremia
viru
replic
lung
infect
rash
appear
radiolog
patholog
find
consist
result
rtpcr
viru
isol
enhanc
challeng
dose
may
success
establish
faith
clinic
diseas
model
find
studi
show
dose
g
protect
monkey
challeng
pfu
sarscov
strain
dose
g
confer
complet
protect
immun
anim
although
three
eight
immun
anim
two
lower
dosag
group
show
viru
excret
blood
challeng
evid
present
sampl
anim
well
signific
clinic
symptom
sign
evid
infect
found
anim
receiv
higher
dose
vaccin
three
anim
induc
lower
titer
serum
igg
antibodi
neg
nasoparyng
siga
antibodi
respons
partial
protect
like
result
inadequ
absent
humor
respons
result
indic
inactiv
vaccin
use
appropri
dose
elicit
safe
protect
respons
find
also
impli
crossprotect
obtain
two
differ
viru
strain
use
studi
gener
vaccin
inject
rout
elicit
mostli
humor
antibodi
interestingli
howev
result
show
high
incid
mucos
iga
respons
rhesu
monkey
compar
induc
inactiv
viru
vaccin
human
increas
specif
antibodi
product
mucosa
upper
respiratori
tract
may
import
prevent
sarscov
viru
infect
earli
stage
mucos
surfac
primari
rout
sar
transmiss
specif
igg
antibodi
exhibit
immun
anim
approxim
day
postimmun
inactiv
sarscov
vaccin
continu
increas
appear
enhanc
increas
vaccin
dose
antibodi
titer
induc
high
dose
group
higher
middl
low
dose
group
immun
profil
induc
monkey
present
studi
similar
mice
well
compar
elicit
natur
infect
man
furthermor
antibodi
titer
continu
increas
monkey
accord
week
observ
follow
inocul
show
boost
effect
natur
infect
inactiv
vaccin
immun
studi
also
demonstr
sar
inactiv
vaccin
stimul
rhesu
monkey
produc
specif
antibodi
neutral
activ
nab
level
similar
induc
inactiv
dna
vaccin
mice
studi
higher
induc
adenoviralbas
vaccin
monkey
time
point
hand
result
serum
cytokin
product
vaccin
monkey
suggest
vaccin
preferenti
induc
respons
find
also
impli
inactiv
vaccin
candid
may
enhanc
cellular
immun
respons
includ
increas
product
monkey
product
increas
activ
natur
killer
nk
cell
inhibit
replic
viru
observ
previou
studi
sar
patient
appear
chest
radiograph
improv
viral
load
decreas
interleukin
proinflammatori
cyokin
increas
whether
specif
cellular
immun
respons
also
induc
inactiv
vaccin
need
investig
toxic
vaccin
monkey
extrem
low
dose
g
caus
clinic
sign
biochem
evid
two
inject
local
reaction
immun
monkey
mild
high
dosag
group
absent
vaccin
group
conclud
vaccin
well
toler
experiment
anim
inject
intramuscularli
without
appreci
risk
advers
effect
note
antibodi
mediat
enhanc
ade
discov
coronaviru
ade
fipv
infect
human
cell
line
administr
inactiv
vaccin
sensit
cat
subsequ
antibodi
depend
enhanc
infect
lead
sever
periton
death
therefor
research
concern
whether
ade
occur
sarscov
inactiv
vaccin
consid
time
known
whether
anim
model
faith
replic
complex
patholog
symptomatolog
human
diseas
necessari
test
potenti
sar
vaccin
candid
immunogen
safeti
efficaci
human
event
futur
outbreak
